Skip to main content
Premium Trial:

Request an Annual Quote

Hennessey Elected Director of Repligen

Premium

NEEDHAM, Mass.--Robert Hennessey, chairman, president, and CEO of Genome Therapeutics in Waltham, Mass., has been elected a director of Repligen here. Repligen develops combinatorial chemistry synthesis and high-throughput screening technologies for the accelerated discovery of new drugs capable of blocking certain protein-carbohydrate and protein-protein interactions, for application in cancer and inflammatory disorders. Hennessey joined Genome Therapeutics in 1993 and refocused the company on genomics. He is also a director of PenWest Pharmaceuticals and Virus Research Institute.

Filed under

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.